Toward the development of a protein-based group B Streptococcus vaccine

Clinical trials of protein-based vaccines to prevent Group B streptococcal infections are underway. In this issue of Cell Reports Medicine, Pawlowski et al.(1) provide an extensive characterization of the immune response generated by the recently tested GBS-NN vaccine.

Detalles Bibliográficos
Autores principales: Dominguez, Kristen, Randis, Tara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Preview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861943/
https://www.ncbi.nlm.nih.gov/pubmed/35243427
http://dx.doi.org/10.1016/j.xcrm.2022.100536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861943/
https://www.ncbi.nlm.nih.gov/pubmed/35243427
http://dx.doi.org/10.1016/j.xcrm.2022.100536

Ejemplares similares